170 related articles for article (PubMed ID: 38671526)
1. REPeated mAgnetic resonance Image-guided stereotactic body Radiotherapy (MRIg-reSBRT) for oligometastatic patients: REPAIR, a mono-institutional retrospective study.
Chiloiro G; Panza G; Boldrini L; Romano A; Placidi L; Nardini M; Galetto M; Votta C; Campitelli M; Cellini F; Massaccesi M; Gambacorta MA
Radiat Oncol; 2024 Apr; 19(1):52. PubMed ID: 38671526
[TBL] [Abstract][Full Text] [Related]
2. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
3. Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis.
Stera S; Balermpas P; Chan MKH; Huttenlocher S; Wurster S; Keller C; Imhoff D; Rades D; Dunst J; Rödel C; Hildebrandt G; Blanck O
Strahlenther Onkol; 2018 Feb; 194(2):143-155. PubMed ID: 28875297
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence.
Berkovic P; Gulyban A; Nguyen PV; Dechambre D; Martinive P; Jansen N; Lakosi F; Janvary L; Coucke PA
Clin Colorectal Cancer; 2017 Dec; 16(4):349-357.e1. PubMed ID: 28462852
[TBL] [Abstract][Full Text] [Related]
6. Functional image-guided stereotactic body radiation therapy planning for patients with hepatocellular carcinoma.
Tsegmed U; Kimura T; Nakashima T; Nakamura Y; Higaki T; Imano N; Doi Y; Kenjo M; Ozawa S; Murakami Y; Awai K; Nagata Y
Med Dosim; 2017 Summer; 42(2):97-103. PubMed ID: 28433483
[TBL] [Abstract][Full Text] [Related]
7. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
[TBL] [Abstract][Full Text] [Related]
8. Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer.
Schaule J; Chamberlain M; Wilke L; Baumgartl M; Krayenbühl J; Zamburlini M; Mayinger M; Andratschke N; Tanadini-Lang S; Guckenberger M
Radiat Oncol; 2021 Sep; 16(1):189. PubMed ID: 34565439
[TBL] [Abstract][Full Text] [Related]
9. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
[TBL] [Abstract][Full Text] [Related]
10. A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.
Kimura T; Takeda A; Tsurugai Y; Kawano R; Doi Y; Oku Y; Hioki K; Miura H; Nagata Y
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1265-1275. PubMed ID: 32712256
[TBL] [Abstract][Full Text] [Related]
11. Long-term characterization of MRI-morphologic alterations after active motion-compensated liver SBRT: a multi-institutional pooled analysis.
Dreher C; Sarria GR; Miebach G; Weiss C; Buergy D; Wojtal P; Tavakoli AA; Krug D; Oppitz H; Giordano FA; Both M; Lohr F; Dunst J; Blanck O; Boda-Heggemann J
Acta Oncol; 2023 Mar; 62(3):281-289. PubMed ID: 37017543
[TBL] [Abstract][Full Text] [Related]
12. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.
Yeung R; Hamm J; Liu M; Schellenberg D
Radiat Oncol; 2017 Jun; 12(1):105. PubMed ID: 28637480
[TBL] [Abstract][Full Text] [Related]
13. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis.
Yoon SM; Luterstein E; Chu FI; Cao M; Lamb J; Agazaryan N; Low D; Raldow A; Steinberg ML; Lee P
Cancer Med; 2021 Sep; 10(17):5897-5906. PubMed ID: 34288538
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
16. Repeated SBRT for in- and out-of-field recurrences in the liver.
Gkika E; Strouthos I; Kirste S; Adebahr S; Schultheiss M; Bettinger D; Fritsch R; Brass V; Maruschke L; Neeff HP; Lang SA; Nestle U; Grosu AL; Brunner TB
Strahlenther Onkol; 2019 Mar; 195(3):246-253. PubMed ID: 30353350
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases: Who Will Benefit the Most from SBRT?
Park HJ; Kim HJ; Won JH; Lee SC; Chang AR
Technol Cancer Res Treat; 2015 Apr; 14(2):159-67. PubMed ID: 24502552
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes.
Mazzola R; Cuccia F; Figlia V; Rigo M; Nicosia L; Giaj-Levra N; Ricchetti F; Vitale C; Mantoan B; Di Paola G; De Simone A; Gurrera D; Sicignano G; Naccarato S; Ruggieri R; Alongi F
Radiol Med; 2021 Jul; 126(7):989-997. PubMed ID: 33835309
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]